Spoken Alpha
KALA BIO, Inc.
Kala Bio designs and develops artificial intelligence infrastructure platforms for biotechnology and pharmaceutical companies, with a focus on on-premises deployment that allows customers to leverage advanced AI capabilities while maintaining control over proprietary data.
KALA BIO, Inc is a Healthcare company operating in Biotechnology with a $10.1M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 18, 2026).
6 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for KALA.
$ curl https://api.spokenalpha.com/v1/companies/KALAFAQ
Spoken Alpha indexes KALA's earnings call transcripts at https://spokenalpha.com/companies/KALA. Each call links to attributed speakers and parsed analyst Q&A.
KALA BIO, Inc. (KALA) held its most recent earnings call on 2022-08-12, covering fiscal Q2 2022.
KALA BIO, Inc. (KALA) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-18 | $-21.32 | — | — | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-28 | $-0.14 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-18 | $-53.50 | $-50.50 | -5.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $-65.94 | $-102.00 | +35.4% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-50.66 | $-127.00 | +60.1% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-26 | $-1.23 | $-2.47 | +50.1% | $254.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-96.50 | $-135.50 | +28.8% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-122.27 | $-229.00 | +46.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-4.19 | $-2.89 | -45.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-28 | $-79.07 | $-200.00 | +60.5% | $70.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-150.12 | $23.00 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-03 | $-174.05 | $-214.50 | +18.9% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-6.99 | $-4.52 | -54.6% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-02 | $-323.17 | $-382.50 | +15.5% | $1.2M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-449.33 | $1450.00 | -100.0% | $420.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-872.50 | $-900.00 | +3.1% | $2.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-1001.00 | $-720.10 | -39.0% | $1.4M | — | — | EODHD |
| Q4 FY2021 | 2022-03-28 | $-34.00 | $-20.33 | -67.2% | $1.9M | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-925.00 | $-978.61 | +5.5% | $3.1M | — | — | EODHD |
| Q2 FY2021 | 2021-08-04 | $-1000.00 | $-975.30 | -2.5% | $3.1M | — | — | EODHD |
Source: EODHD. KALA reported actuals as published; sparse fields render as —.